Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Glipizide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    20 result(s) found for: Glipizide. Displaying page 1 of 1.
    EudraCT Number: 2004-002159-16 Sponsor Protocol Number: 0431-024 Start Date*: 2004-11-03
    Sponsor Name:Suomen MSD Oy
    Full Title: A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 Compared With Sulfonylurea Therapy in Patients With Type 2 Diabetes With Inadequate Glyc...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    7.0 10045242 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) DK (Completed) AT (Completed) LT (Completed) HU (Completed) CZ (Completed) GB (Completed) IT (Completed) DE (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-000959-10 Sponsor Protocol Number: SYR-322_303 Start Date*: 2008-11-20
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Limited,
    Full Title: A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Subjects with Type 2 Diabetes
    Medical condition: Type II diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003548-32 Sponsor Protocol Number: 0431-063 Start Date*: 2007-09-27
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency Who Have ...
    Medical condition: Type II Diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FR (Completed) DE (Completed) IT (Completed) AT (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005220-33 Sponsor Protocol Number: D1690C00004 Start Date*: 2008-02-08
    Sponsor Name:AstraZeneca AB
    Full Title: A 52-Week, International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III study with a 156-Week Extension Period to Evaluate the Efficacy and Safety of Dapaglif...
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029505 Non-insulin-dependent diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed) FR (Completed) NL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-007444-34 Sponsor Protocol Number: SYR-322_305 Start Date*: 2009-06-29
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd.
    Full Title: A Multicenter, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Durability of the Efficacy and Safety of Alogliptin Compared to Glipizide When Used in Combination with Metformin in...
    Medical condition: Patients with type II diabetes mellitus (T2DM) who are currently treated with a stable daily dose of metformin alone but experiencing inadequate glycemic control
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) LT (Completed) LV (Completed) AT (Completed) ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003529-26 Sponsor Protocol Number: 0431-073 Start Date*: 2008-01-18
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes Mellitus and End-Stage Renal Disease Who Are on Di...
    Medical condition: Type II Diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003998-55 Sponsor Protocol Number: D1680C00001 Start Date*: 2007-11-27
    Sponsor Name:AstraZeneca AB
    Full Title: A 52-Week International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III study with a 52-Week Extension Period to Evaluate the Safety and Efficacy of Saxaglipti...
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029505 Non-insulin-dependent diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) NL (Completed) HU (Completed) SK (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-002332-85 Sponsor Protocol Number: MK-3102-019 Start Date*: 2013-03-14
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of MK-3102 Versus Placebo in Subjects with Type 2 Diabetes Mellitus with Moderate or Severe Chronic Kidn...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    17.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) PL (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-012612-41 Sponsor Protocol Number: D1020C00009 Start Date*: 2009-11-24
    Sponsor Name:AstraZeneca AB
    Full Title: A 4-month, Randomized, Double-blind, Placebo- and Active-Controlled, Multi-centre, Parallel-Group study, with an Optional 2-Month Extension, to Evaluate Efficacy, Safety and Tolerability of AZD1656...
    Medical condition: Type 2 diabetes mellitus patients on metformin treatment
    Disease: Version SOC Term Classification Code Term Level
    12.0 10067585 Type 2 diabetes mellitus LLT
    12.0 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) LV (Completed) SE (Completed) LT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2006-007070-30 Sponsor Protocol Number: glipizide PKPD Start Date*: 2007-06-07
    Sponsor Name:Stockholms Läns Landsting
    Full Title: Farmakokinetik och effekt av glipizid på insulin och glukos hos patienter med nyupptäckt typ 2-diabetes mellitus
    Medical condition: diabetes mellitus typ 2
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004090-29 Sponsor Protocol Number: AVD100521 Start Date*: 2005-02-07
    Sponsor Name:GlaxoSmithKline Research & Development Ltd [...]
    1. GlaxoSmithKline Research & Development Ltd
    2. GlaxoSmithKline R&D
    Full Title: A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone versus Glipizide on the Progression of Atherosclerosis in Subjects with Type ...
    Medical condition: atherosclerosis in Type 2 Diabetes Mellitus patients with cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    7.1 10003601 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) LV (Completed) IT (Completed) CZ (Completed) GR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-000312-93 Sponsor Protocol Number: 0431-020 Start Date*: 2004-08-02
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 to Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metfor...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    7.0 10045242 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) DK (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002160-22 Sponsor Protocol Number: 0431-028 Start Date*: 2004-11-17
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety of MK-0431 Monotherapy in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency Who Have Inadequate Glycemic Co...
    Medical condition: Type 2 Diabetes Mellitus Chronic Renal Insufficiency [MedDRA classification code: 10050441]
    Disease: Version SOC Term Classification Code Term Level
    7.0 10045242 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-000284-27 Sponsor Protocol Number: UOLDR0001N Start Date*: 2011-05-16
    Sponsor Name:University of Leicester
    Full Title: A Randomised Controlled Trial for People with Established Type 2 Diabetes during Ramadan: Liraglutide versus a Sulphonylurea and/or Pioglitazone
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-001144-71 Sponsor Protocol Number: D6160C00032 Start Date*: 2004-10-22
    Sponsor Name:AstraZeneca AB
    Full Title: A 24-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy when Added to the Therapy of Pat...
    Medical condition: Patients diagnosed with type 2 diabetes and treated with a single or multiple oral antidiabetic agents
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-002549-11 Sponsor Protocol Number: D6160C00038 Start Date*: 2005-06-20
    Sponsor Name:AstraZeneca AB
    Full Title: An Open-label, Multi-Centre and Long-Term Extension Study to Evaluate the Safety and Tolerability of oral Tesaglitazar 1 mg in patients with Type 2 Diabetes.
    Medical condition: Type II Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    7 10045242 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) HU (Completed) CZ (Completed) SK (Completed) EE (Completed) LV (Completed) LT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002104-91 Sponsor Protocol Number: UNOLE0527 Start Date*: 2016-03-22
    Sponsor Name:University of Leicester
    Full Title: A Randomised Controlled Trial for People with Established Type 2 Diabetes during Ramadan: Canagliflozin (Invokana™) vs. standard dual therapy regimen: The ‘Can Do Ramadan’ Study
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-000997-77 Sponsor Protocol Number: GS-US-259-0110 Start Date*: 2012-02-28
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Ranolazine When Added to Glimepiride in Subjects with Type 2 Diabetes Mellitus
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) PL (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2006-005192-18 Sponsor Protocol Number: A5351022 Start Date*: 2007-03-15
    Sponsor Name:Pfizer Ltd.
    Full Title: A 1-YEAR, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CP-945,598 IN THE TREATMENT OF OVERWEIGHT, ORAL AGENT-TREATED SUBJECTS WITH TYPE 2 DIABET...
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029883 Obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) SK (Completed) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001258-94 Sponsor Protocol Number: A2171018 Start Date*: 2005-12-23
    Sponsor Name:Pfizer Pharma GmbH
    Full Title: One Year, Open-Label Outpatient, Parallel Group Trial Assessing the Impact of the Availability of Inhaled Insulin (Exubera®) on Glycemic Control in Patients with Type 2 Diabetes Mellitus Who Are Po...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    7 10012601 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 09 12:13:36 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA